Breaking News
Global News
Chola Securities in News
Sessions News
Economy News
Nifty 50
Sensex
Nifty Bank
Bankex
Nifty 100
BSE Sensex 50
Nifty Financial Services
BSE Sensex Next 50
Nifty Midcap 100
BSE Bharat 22
Nasdaq
DJIA
S&P 500
Hang Seng
Nikkei 225
Straits Times
FTSE 100
KLSE Composite
Jakarta Composite
Exchange Holiday List
Historical Returns
Top Gainers
Top Losers
52 Week High
52 Week Low
Most Active by Value
Most Active by Volume
Out Performer
Under Performer
Advances & Declines
Only Buyers and Sellers
Bulk deal
Block deal
Nifty Futures
Nifty Options
Bank Nifty Futures
Bank Nifty Options
Stock Futures
Stock Options
Increase in OI
Decrease in OI
Highest in OI
Lowest in OI
All Index Futures
Most Active Contracts
Most Active Call
Most Active Put
Solutions
Platforms
Research
More
Markets
Become a partner
3i Infotech has received an IT services contract worth Rs 37.05 crore from Hindustan Petroleum Corporation (HPCL), for providing Facility Management Services (FMS) across HPCL locations for three years.
The engagement involves providing IT services across HPCL's Corporate R&D Centre, Visakh Refinery, Head Office, Zones, ISC and multiple PAN India locations. The scope includes skilled manpower support, desktop and endpoint support, printer and scanner support, server support, VMS endpoint support, travel assistance and related IT infrastructure support services.
Under this engagement, company will support HPCL's distributed IT operations through managed infrastructure services, enabling continuity, operational efficiency and reliable support across critical business locations.
Alembic Pharmaceuticals has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Larotrectinib Capsules, 25 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vitrakvi Capsules, 25 mg and 100 mg, of Bayer Healthcare Pharmaceuticals Inc. (Bayer).
Larotrectinib is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: a) have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, b) are metastatic or where surgical resection is likely to result in severe morbidity, and c) have no satisfactory alternative treatments or that have progressed following treatment.
Larotrectinib Capsules, 25 mg and 100 mg, have an estimated market size of US$ 91 million for twelve months ending March 2026 according to IQVIA.
on Chola Securities Mobile & Web App.
Stay organised, informed & in control while accessing your portfolio, reports, trading tools and service requests—all in one seamless platform.